AQST stock forecast, quote, news & analysis
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs... Show more
Why Aquestive Therapeutics (AQST) Stock Is Up +15.2% in the Last 30 Days
Key Takeaways
- Aquestive Therapeutics (AQST) shares rose approximately 15.2% over the last 30 days, climbing from $4.09 to $4.71, driven by strong Q1 2026 earnings and renewed regulatory momentum.
- The company beat Wall Street revenue and EPS estimates, reporting Q1 revenue of $14.45 million versus a consensus of $10.9 million, and a narrower-than-expected loss per share.
- A $150 million debt refinancing with Oaktree Capital strengthened the balance sheet and signaled institutional confidence ahead of the potential Anaphylm launch.
- Over the last quarter, AQST has staged a broader recovery from January 2026 lows, supported by progress on the Anaphylm NDA resubmission pathway and positive analyst coverage.
- Analyst consensus remains a Strong Buy with a 12-month price target of $8.89, reflecting significant upside expectations tied to pipeline execution.
Aquestive Therapeutics (AQST) Company Overview and Market Position
Aquestive Therapeutics is a specialty pharmaceutical company focused on developing and commercializing orally administered and topical gel products that deliver complex molecules through its proprietary PharmFilm technology. The company's portfolio includes FDA-approved products such as Libervant (diazepam buccal film) for seizure treatment, Sympazan (clobazam oral film) for epilepsy, and AZSTARYS for ADHD. Aquestive also manufactures Suboxone sublingual film for opioid dependence under license. The company's lead pipeline candidate, Anaphylm (epinephrine sublingual film), is in development as a needle-free alternative to epinephrine autoinjectors for emergency treatment of severe allergic reactions, including anaphylaxis. With a market capitalization of approximately $520 million, Aquestive occupies a niche position in the drug delivery space, attracting investor attention for its potential to disrupt the epinephrine market and expand its CNS-focused product lineup.
Aquestive Therapeutics (AQST) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, AQST shares advanced from a closing price of $4.09 on May 19, 2026, to $4.71 on June 18, 2026, representing a gain of approximately 15.2%. The move was punctuated by a sharp 14.5% single-day surge on May 14 following the Q1 earnings release, though the stock gave back roughly 11.8% the following session as traders locked in profits. Since mid-May, the stock has steadily rebuilt upward momentum, closing higher in nine of the last fifteen trading sessions of the measured period.
Zooming out to the quarterly view, AQST has delivered a broader recovery. After a punishing January 2026 that saw shares fall over 54% amid concerns about the Anaphylm NDA filing, the stock rebounded more than 35% in February and has continued to grind higher through the spring. From mid-March levels around $4.00 to the current price near $4.71, the stock has added roughly 18% over the quarter, reflecting improving sentiment as regulatory clarity and financial milestones materialize.
What Drove AQST Stock Price in the Last 30 Days
The primary catalyst behind the 30-day rally was the company's first-quarter 2026 earnings report released on May 13. Aquestive posted revenue of $14.45 million, handily surpassing the consensus estimate of $10.9 million, while its net loss per share of $0.07 beat expectations of a $0.13 loss. The earnings beat was accompanied by an upbeat business update highlighting rapid progress on the Anaphylm NDA resubmission, which remains on track for the third quarter of 2026.
Just before earnings, Aquestive completed a $150 million debt refinancing with Oaktree Capital on May 12, replacing existing debt with more favorable terms and bolstering the company's cash position to approximately $110.7 million. This move was widely interpreted as a vote of confidence from a sophisticated institutional lender and provided greater financial flexibility for the anticipated commercial launch of Anaphylm.
Analyst activity also supported the stock. Oppenheimer initiated coverage with an Outperform rating and an $8 price target in late April, while multiple firms reiterated Buy ratings following the Q1 report. The company's annual shareholder meeting in early June reinforced the message of steady progress toward FDA approval and global regulatory filings for Anaphylm, further sustaining positive sentiment.
What Drove AQST Stock Performance Over the Last Quarter
The quarterly narrative for AQST is one of recovery and rebuilding. The stock entered the quarter battered by a January selloff triggered when the FDA identified deficiencies in the original Anaphylm NDA submission, prompting a sharp analyst downgrade from Cantor Fitzgerald and a wave of shareholder litigation. However, the company moved quickly to address concerns, completing a Type A meeting with the FDA in March that clarified the path forward and established a Q3 2026 resubmission timeline.
Throughout the quarter, Aquestive methodically executed on its remediation plan, expanded its medical affairs and commercial teams in preparation for a potential launch, and advanced international regulatory filings. The Q1 earnings beat in May served as a powerful inflection point, validating that the underlying business — including manufacturing revenue from licensed products — was performing above expectations even as the pipeline narrative regained credibility. The combination of operational execution, strengthened balance sheet, and tangible regulatory progress has reshaped the stock's trajectory from crisis management to cautious optimism.
Trending AI Robots
For traders seeking to complement their own research with data-driven automation, Tickeron's Trending AI Robots page offers a curated view of top-performing AI trading bots. Tickeron operates hundreds of AI-powered trading bots that actively trade thousands of tickers across diverse strategies, timeframes, and market conditions. Rather than displaying every available bot, the Trending AI Robots section highlights only those that have demonstrated standout performance and relevance in current market environments. Each bot is designed with a distinct approach — ranging from short-term momentum strategies to longer-term trend-following models — and includes transparent performance metrics for evaluation. Exploring this page can help traders identify automated tools that align with their investment style and objectives.
AQST Stock Forecast Drivers: What Investors Should Watch Next
The most consequential event on the horizon for AQST is the planned Anaphylm NDA resubmission to the FDA, expected in the third quarter of 2026. The outcome of this regulatory filing will likely be the single largest determinant of the stock's direction in the months ahead, as Anaphylm represents a potential blockbuster opportunity in the epinephrine market. Investors should also monitor the FDA's acceptance of the resubmission and the subsequent six-month review timeline.
Beyond Anaphylm, the company's early-stage pipeline — including AQST-108, a topical gel in Phase 2 trials for alopecia areata — offers additional long-term optionality. Financially, the next quarterly earnings report, estimated for August 11, 2026, will provide updated revenue guidance and cash burn metrics. Macroeconomic factors, including interest rate policy and biotech sector sentiment, may also influence the stock. Competitive developments in the epinephrine and CNS drug delivery spaces, as well as any further legal or regulatory developments related to the class action lawsuits filed earlier in 2026, round out the key risk factors that investors should continue to track.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
AQST's Stochastic Oscillator is staying in oversold zone for 3 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The 10-day moving average for AQST crossed bullishly above the 50-day moving average on June 18, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AQST advanced for three days, in of 253 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 186 cases where AQST Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for AQST moved out of overbought territory on June 25, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on June 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AQST as a result. In of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for AQST turned negative on June 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .
AQST moved below its 50-day moving average on July 02, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AQST declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
AQST broke above its upper Bollinger Band on June 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (79.618). P/E Ratio (0.000) is within average values for comparable stocks, (97.708). AQST's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.629). Dividend Yield (0.000) settles around the average of (0.035) among similar stocks. P/S Ratio (10.672) is also within normal values, averaging (95.237).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AQST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AQST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer thin film pharmaceutical and over the counter drug products
Industry PharmaceuticalsGeneric